Target Validation is the most critical step in the Drug Discovery process, almost everything else we can fix. Which is why the update to the Open Targets Platform is so valuable.

The latest release of the Open Targets Platform - 20.09 - is now available at https://www.targetvalidation.org/.

This release sees the addition of ClinGen to the expert curated evidence sources for rare disease genetics that includes UniProt, the Genomics England PanelApp, and Gene2Phenotype.

This latest update includes 27,610 Targets, 13,944 Diseases, 8,419,186 Evidence and 6,551,303 Associations